BOSTON, May 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 21st 2019, at 2:30pm ET. A ...
BOSTON, April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, recently presented positive results from its ophthalmic programs in dry age-related macular degeneration (AMD) and Leber's hereditary optic ...
WARRINGTON, Pa., April 30, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biopharmaceutical and medical device company focused on developing novel therapies to address significant unmet needs in important acute care markets, today announced it has appointed Daniel Geffken to the Company's Board of Directors, effective April 24, 2019. "As we continue to support Windtree in ...
BOSTON, April 25, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of enrollment for MMPOWER-3 (SPIMM-301), with top-line data expected by year end. MMPOWER-3 is a Phase 3, randomized, ...
BOSTON, April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from the open-label extension of the Phase 2/3 TAZPOWER study of elamipretide, an investigational drug, in patients ...
BOSTON, April 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2018 and announced recent business highlights. "In 2018, we executed across ...
BOSTON, April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8th, at ...
BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular ...
BOSTON, March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has issued an additional 588,232 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, resulting ...
Amelia Stetler, 617-762-2562media@stealthbt.com